Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2252W HIGH $2.16
Volume
112.89 K
Value Traded
321.62 K
Short % Float
5.03%
Days to Cover
1.0
-2.03%Week
-66.76%1 Month
+80.28%3 Month
-6.76%6 Month
-86.38%5 Year
-86.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.89 M
EPS (TTM)
-1.71
P/E Ratio
-
Ent. Value
-735.26 K
Total Shares
3.39 M
Float Shares
2.25 M
Insiders
33.61%
Institutions
4.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KAPA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kairos Pharma, Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kairos Pharma, Ltd.
51Total events
1Upcoming
16Tier-1 (high impact)
2024 to 2027Coverage
Event history 42
▲Interim Efficacy DataENV-105Clinical Data
Positive interim efficacy data from Phase 2 trial of ENV-105 plus apalutamide in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Protocol AmendmentENV-105Trial
Phase 2 protocol modified to enroll patients earlier in disease progression
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Partnership / LicenseENV-105Corporate
Strategic collaboration with Bayer to evaluate ENV-105 in combination with XOFIGO
metastatic castration-resistant prostate cancer (mCRPC) involving bonesource ↗
◆Safety Data UpdateENV-105Clinical Data
Interim safety data from Phase 1 trial of ENV-105 in combination with osimertinib
EGFR-mutated non-small cell lung cancersource ↗
◆Topline ReadoutENV-105Clinical Data
Key safety and efficacy results for ENV-105 Phase 1 NSCLC trial
non-small cell lung cancersource ↗
▲Partnership / LicenseCL-741Corporate
Signed term sheet to acquire worldwide rights for CL-741
non-small cell lung cancer (NSCLC) and esophageal and gastric cancersource ↗
◆Partnership / LicenseENV-105Corporate
Develop key collaborations testing synergy of ENV-105 with oncology drugs for prostate cancer
prostate cancersource ↗
▲Partnership / LicenseCL-273Corporate
Signing of binding terms to acquire CL-273 from Celyn Therapeutics
EGFR-mutant non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
Signing of term sheet for strategic asset acquisition of CL-273 and CL-741 from Celyn Therapeutics
▲Oral PresentationENV-105Presentation
Kairos Pharma wins 2025 Clinical Trials Arena Research and Development Excellence Award for ENV-105 in advanced prostate cancer
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationENV-105Presentation
Presentation of preliminary safety and clinical activity from Phase 2 study of ENV105 at ESMO 2025
advanced, castration-resistant prostate cancersource ↗
◆Oral PresentationENV-105Presentation
Virtual KOL event to discuss interim efficacy results of ENV105 in advanced prostate cancer
advanced prostate cancersource ↗
◆Interim AnalysisENV-105Trial
Interim efficacy results from Phase 2 trial of ENV105 in advanced prostate cancer
advanced prostate cancersource ↗
◆Enrollment UpdateENV-105Trial
Trial accruing patients; aims to enroll 100 patients total
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationENV-105Presentation
Presentation of initial Phase 1 data of ENV105 in combination with osimertinib for EGFR-mutated NSCLC at World Lung Cancer Conference
non-small cell lung cancersource ↗
◆Interim AnalysisENV-105Trial
Interim efficacy data expected from Phase 2 trial of ENV-105
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Safety Data UpdateENV-105Clinical Data
Positive interim safety results from Phase 2 trial of ENV-105 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Safety Data UpdateENV-105Clinical Data
Interim safety analysis of ENV105 in combination with apalutamide
advanced prostate cancersource ↗
◆Oral PresentationKROS-101Presentation
Presentation of GITR ligand small molecule agonist data at ASCO
cancersource ↗
◆Interim AnalysisENV-105Trial
Safety and interim efficacy results for ENV105 Phase 1 lung cancer trial
EGFR-dependent non-small cell lung cancersource ↗
▲PublicationENV-105Presentation
Peer-reviewed publication on CD105 blockade restoring osimertinib sensitivity in EGFR-mutant NSCLC
non-small cell lung cancersource ↗
◆Poster PresentationPresentation
Preclinical data presented at AACR IO 2025 for KROS 101 in melanoma and glioblastoma
melanoma, glioblastomasource ↗
◆Poster PresentationPresentation
Preclinical data presented at AACR IO 2025 for KROS 401 in glioma
gliomasource ↗
◆Oral PresentationPresentation
Oral presentation of preclinical data on KROS 101 at AACR-JCA Joint Conference
melanoma and glioblastomasource ↗
▲Topline ReadoutENV-105Clinical Data
Positive interim safety and efficacy results for ENV-105 in combination with apalutamide in advanced prostate cancer
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Interim AnalysisENV-105Trial
Positive interim efficacy data from Phase 2 trial: median PFS >13 months
castrate resistant prostate cancersource ↗
●Oral PresentationENV-105Presentation
Presentation of Phase 2 interim data at 2025 ESMO Congress
castrate resistant prostate cancersource ↗
▲Partnership / LicenseENV-105Corporate
Collaboration with PreCheck Health Services to develop companion biomarkers for ENV105
prostate cancer, lung cancersource ↗
▲First Patient DosedENV-105Trial
First patient dosed in Phase 2 trial of ENV105 with apalutamide for CRPC
castrate resistant prostate cancersource ↗
▲First Patient DosedENV-105Trial
First two patients dosed in Phase 1 trial of ENV105 in combination with osimertinib
non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How KAPA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 98%
Micro Cap(rank 644 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every KAPA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ENV-105 | metastatic castration-resistant prostate cancer | Phase 2 | 2026-10-06 | statistically significant improvement in progression-free survivalRead More | Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Murali RamachandranOfficer (VP of Research and Development) | Buy | 200 133,057 held | $1.59 | 11/25/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in KAPA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KAPA for Q2 2026. | ||||
KAPA Institutional Ownership Trends
KAPA Short Interest
Shares sold short, counted twice a month.
5.03%
Short % of Float
of tradable shares sold short
113.2K
Shares Sold Short
-1.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
108.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KAPA ranks across every disease it competes in
Competitive Position is a premium feature
See how KAPA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKAPA News
KAPA▼ -25.8%on this news· ran to -48% by day 3
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Kairos Pharma has announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for treating metastatic castration-resistant prostate cancer. The interim analysis revealed a statistically significant improvement in progression-free survival among patients. This data suggests potential benefits of the treatment in addressing drug resistance in cancer.
Read more →KAPAKairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Kairos Pharma, a clinical-stage biopharmaceutical company, announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference. The event is scheduled from September 28 to October 1 at the Sheraton Boston Hotel, with sessions available on demand.
Read more →KAPA▼ -6.2%on this news
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kairos Pharma, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Investment Conference. CEO John Yu will provide a corporate overview on September 14, 2026, at the Lotte New York Palace Hotel. This event aims to showcase the company's efforts in addressing cancer drug resistance.
Read more →KAPA▼ -20%on this news
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Kairos Pharma has announced a 1-for-7 reverse stock split effective September 1, 2026. This action is intended to reduce the number of outstanding shares and increase the per-share trading price, aiding compliance with NYSE American listing requirements. The split will not affect the par value of the common stock or stockholders' ownership percentages.
Read more →KAPA▼ -12.7%on this news
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Kairos Pharma has entered a strategic collaboration with Bayer to assess the efficacy of ENV-105, a novel CD105/BMP signaling inhibitor, in conjunction with Bayer's XOFIGO for treating metastatic castration-resistant prostate cancer. This partnership aims to enhance treatment options for patients suffering from this challenging condition, particularly those with bone metastases.
Read more →KAPA▼ -6.5%on this news
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Kairos Pharma has announced promising interim safety data from its Phase 1 trial of ENV-105, a treatment for advanced EGFR-mutated non-small cell lung cancer. The trial evaluates ENV-105 in combination with osimertinib, aiming to address drug resistance in cancer patients. This milestone highlights the potential of ENV-105 in a lucrative market.
Read more →KAPAKairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Kairos Pharma Ltd. provided a mid-year update for 2026, highlighting its acquisition of CL-741, a promising oncology asset targeted for non-small cell lung cancer. The company plans to leverage its expertise in drug resistance therapeutics to advance its pipeline, with several key clinical milestones expected in the coming months. Financially, Kairos maintains a robust position with over $8 million secured in non-dilutive funding. However, the company acknowledges inherent risks related to clinical trials and regulatory approvals that could impact anticipated outcomes.
Read more →KAPA▲ +6.1%on this news
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
Kairos Pharma Ltd. has been awarded the Leaders in Drug Resistance Development award by GHP Magazine for 2026. This recognition underscores the company's innovative efforts in combating drug resistance in cancer treatments. CEO Dr. John Yu highlighted the importance of addressing drug resistance to enhance patient outcomes. The award reflects Kairos Pharma's commitment to advancing cancer therapeutics.
Read more →KAPA▼ -5.4%on this newsshared move
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
Kairos Pharma, Ltd. has announced the date for its Annual Meeting of Shareholders, set for June 29, 2026. The company provided an update on its financial filings, highlighting an audit report that emphasizes the need for ongoing concern. Kairos Pharma is focused on innovative cancer therapeutics, with its lead candidate ENV105 currently in clinical trials for prostate and lung cancer.
Read more →KAPAKairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Kairos Pharma Ltd. has been awarded the 2026 Pinnacle Award for Healthcare Innovation as an Emerald honoree for its innovative solutions in combating cancer drug resistance. The company focuses on developing resistance-modulating treatments, particularly ENV-105, an investigational antibody designed to enhance the effectiveness of existing cancer therapies. This recognition highlights Kairos Pharma's commitment to improving cancer care.
Read more →KAPAKairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Kairos Pharma has signed binding terms to acquire CL-273 from Celyn Therapeutics, aiming to enhance its pipeline for EGFR-mutant lung cancer therapies. This investigational drug is designed to target resistant mutations and is backed by significant investment. The acquisition is expected to position Kairos Pharma strongly in a lucrative market projected to reach $16.2 billion by 2026.
Read more →KAPA▼ -12.2%on this newsshared move
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. has signed a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, focusing on non-small cell lung cancer (NSCLC). The assets include CL-273, a pan-EGFR inhibitor, and CL-741, a c-MET kinase inhibitor. This acquisition aims to enhance Kairos's oncology pipeline and address significant unmet medical needs in cancer treatment. The company plans to leverage its clinical infrastructure to expedite development.
Read more →KAPAKairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
Kairos Pharma Ltd. will present at the DealFlow Discovery Conference on January 28-29, 2026, in Atlantic City, NJ. Chief Scientific Officer Neil Bhowmick will deliver a presentation and hold one-on-one investor meetings. The company is advancing its lead candidate, ENV-105, which targets CD105 to combat drug resistance in cancer therapies.
Read more →KAPAKairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
Kairos Pharma Ltd. has been awarded the 2025 Clinical Trials Arena Excellence Award for its innovative work in advanced prostate cancer. The award recognizes the development of ENV-105, a monoclonal antibody targeting CD105, which has shown promising interim results in a Phase 2 trial. The therapy aims to restore sensitivity to hormone treatments in patients with metastatic castration-resistant prostate cancer.
Read more →KAPAKairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 Angeles, CA - October 7, 2025 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company
Kairos Pharma, a clinical-stage biopharmaceutical company, will present positive safety and efficacy data from a Phase 2 trial focusing on advanced, castration-resistant prostate cancer at the ESMO Congress in Berlin. The study evaluates the combination of apalutamide and carotuximab in men who have shown resistance to previous hormone therapies. This trial is particularly relevant as metastatic castration-resistant prostate cancer poses significant challenges in treatment, highlighting the potential effectiveness of Kairos’s investigational therapy. The presentation is scheduled for October 17-21, 2025.
Read more →KAPA▼ -20.2%on this news· ran to -32% by day 3
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
Kairos Pharma has announced positive interim efficacy data from its Phase 2 trial of ENV105 for advanced prostate cancer, demonstrating a median progression-free survival of over 13 months. The trial utilized a combination of ENV105 and the hormone therapy apalutamide, highlighting the drug's potential in treating metastatic castration-resistant prostate cancer. The study, which aims to enroll 100 patients, noted that the treatment was well tolerated without severe toxicities. A virtual KOL discussion will be hosted to further analyze this data.
Read more →KAPAKairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer to feature principal investigators from the trial
Kairos Pharma, a clinical-stage biopharmaceutical company, announced a virtual KOL event to discuss interim efficacy results of ENV105 in a Phase 2 trial for advanced prostate cancer. Scheduled for September 18th, the event will feature insights from principal investigators. Positive interim safety results show that ENV105 is well tolerated in combination with apalutamide, highlighting its potential role in addressing drug resistance in cancer therapy. This development aims to provide a safe alternative for patients facing castration-resistant prostate cancer.
Read more →KAPAKairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
Kairos Pharma, Ltd. has announced the presentation of initial Phase 1 data on its drug ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer. The presentation is scheduled for the World Lung Cancer Conference taking place from September 6-9, 2025, in Barcelona, Spain. The open-label trial primarily aims to evaluate the safety and tolerability of this combination therapy. ENV105 targets CD105, a protein implicated in drug resistance, addressing significant unmet needs in cancer treatment. The company continues to pursue additional trials to validate the efficacy of this novel approach.
Read more →KAPA▲ +70.8%on this news
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive safety results from the ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The interim analysis showed that the treatment was well tolerated alongside standard hormone therapy, with no significant adverse events reported. The study, which aims to enroll a total of 100 patients, is being conducted at several medical centers and aims to evaluate the safety, tolerability, and early efficacy signs of ENV-105. Further efficacy data is expected in September 2025, and Kairos plans to engage with regulatory agencies for potential Phase 3 study design discussions.
Read more →KAPA▲ +19.8%on this news
Dr. John Yu, Chief Executive Officer Kairos Pharma, Ltd. 2355 Westwood Boulevard - Suite 139 Los Angeles, CA 90064
Kairos Pharma, Ltd. has entered into a services agreement with Barretto Pacific Corporation to enhance its investor relations and public presence. The agreement, effective June 10, 2025, outlines a range of services including communication with the investment community, organization of conference calls, and assistance with research reports. This partnership aims to improve the company's engagement with potential investors. However, the agreement comes with a significant financial commitment of $170,000 over the contract's duration.
Read more →About Kairos Pharma, Ltd.
Headquarters2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064
Founded2024
BIOPHARMAWATCH ELITE PLUS
Trade the next KAPA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime